Dong-A to build 100 billion won biosimilar plant in Songdo

Published: 2012-09-06 07:00:00

Updated: 2012-09-06 07:00:00

Korea’s large pharmaceutical company Dong-A Pharmaceutical reaffirmed its intention to advance into the biosimilar market, the company said in regulatory filing on Tuesday .

Biosimilars refer to subsequent versions of biopharmaceutical products following patent and exclusivity expiry on the pr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK